chronic joint inflammation in psoriasis patients
Conditions
Interventions
None listed
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: All patients 18 years or older with a clinical diagnosis of PsO or PsA
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: • Patients, who are not able to provide informed consent. • History of malignancy • Viral or bacterial infection within the past 4 weeks • Patients using anticoagulant therapy • Present or previous use of systemic corticosteroids less than 28 days before enrollment • Present or previous treatment with any cell depleting therapies, including investigational agents. • Presence of any disease for which study subjects need chronic or intermittent immunosuppressive therapy (e.g. prednisolone). • History of chronic viral infection • Recent (
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Frequencies and phenotype of immune cell populations in peripheral lymph nodes (inguinal LNs), skin and joint tissues in psoriatic artritis and psoriasis 2. Differences in immune cell populations profiles (cytokine production, genetic, epigenetic and transcriptional alterations) in peripheral lymph nodes, skin and joint tissues psoriatic artritis and psoriasis | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Frequency and gene expression profiles of stromal cells in lymph nodes of psoriatic artritis and psoriasis patients 2. Frequency and phenotype of immune cells in psoriatic plaque lesions, lymph node and inflamed synovial tissue 3. Gene expression profiles in skin/synovial tissue/lymph node tissue in psoriatic artritis and psoriasis patients | — |
Countries
Netherlands
Outcome results
None listed